Shanghai ChemPartner, a China-based contract research organization and a wholly owned subsidiary of ShangPharma, today announced that it had received the 2009 Most Valuable Partner (MVP) Award from Roche R&D Center China (RRDCC) for excellent service and outstanding contributions in the area of Oncology and Diabetes Pharmacology research, which have successfully helped advance the RRDCC drug discovery project milestones during 2009.
"We are very pleased with the collaboration with ChemPartner on biology research. Our R&D success today would be impossible without the excellent work of collaboration partners like you," Dr. Li Chen, CSO of RRDCC, commented at the award ceremony. "We are riding the same boat. Our collaboration is creating a new model of drug discovery in China."
"We are honored to receive this award and appreciate Roche China's recognition of the efforts and dedication of our talented team of scientists. This award reflects the value and capabilities of ChemPartner's service to our partners," commented Michael Hui, founder and CEO of ChemPartner. "We will continue to focus on the quality of our science, project management and logistics, to add value for our partners R&D programs," Dr. Yuguang Wang, Senior VP of ChemPartner added. "We are also committed to provide intellectual contributions to our customers and partners by leveraging the R&D expertise of our scientific team."
RRDCC MVP awards are presented annually to partners who have done excellent work in collaboration with RRDCC. More than 20 external partners were evaluated in this award competition of 2009.